Prenetics Global Limited (NASDAQ:PRE) Sees Significant Decline in Short Interest

Prenetics Global Limited (NASDAQ:PRE) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 32,800 shares, a drop of 17.6% from the February 13th total of 39,800 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 13,600 shares, the days-to-cover ratio is currently 2.4 days.

Prenetics Global Stock Performance

Prenetics Global stock traded down $0.19 during midday trading on Wednesday, hitting $4.16. 5,807 shares of the company’s stock were exchanged, compared to its average volume of 39,312. The company has a market cap of $50.82 million, a PE ratio of -1.04 and a beta of -0.31. The firm has a 50-day moving average of $5.26 and a two-hundred day moving average of $4.96. Prenetics Global has a 12 month low of $2.85 and a 12 month high of $7.84.

Institutional Investors Weigh In On Prenetics Global

A hedge fund recently bought a new stake in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new position in shares of Prenetics Global Limited (NASDAQ:PRE) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,339 shares of the company’s stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned 0.10% of Prenetics Global as of its most recent SEC filing. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $9.00 target price on shares of Prenetics Global in a report on Thursday, January 16th.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.